The Filing Desk

Arcturus Therapeutics vs Nurix Therapeutics

Arcturus Therapeutics ARCT · Nurix Therapeutics NRIX · Pharmaceuticals

Nurix Therapeutics reported revenue of $84 million in fiscal 2025, about the same as Arcturus Therapeutics' $82 million in fiscal 2025. Arcturus Therapeutics' revenue fell 46.1% in its latest year, and Nurix Therapeutics' grew 54.0%. Arcturus Therapeutics had an operating margin of -93.0%, against -340.2% at Nurix Therapeutics. Free cash flow was −$74 million at Arcturus Therapeutics and −$263 million at Nurix Therapeutics. Their fiscal years end in different months (December 31 and November 30), so the periods don't line up exactly.

Side by side

Arcturus TherapeuticsNurix Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Nov 30, 2025
Revenue$82M$84M
Revenue growth−46.1%54.0%
Revenue growth a year, last 5 years53.9%36.4%
Gross margin——
Operating margin−93.0%−340.2%
Net margin−80.2%−314.9%
Free cash flow−$74M−$263M
Free cash flow margin−90.8%−313.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.4%29.1%
Last close$7.60$13.60
P/E at the last close—5.9×
Insider trades, last 12 months—sold $4.2 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcturus TherapeuticsNurix Therapeutics
Operating margin
Percent of revenue
Arcturus TherapeuticsNurix Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcturus TherapeuticsNurix Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcturus Therapeutics and Nurix Therapeutics pages.